BioArctic AB - New data from LEQEMBI phase 3 Clarity AD study ... - Marketscreener.com
| BIOA-B Stock | SEK 212.40 8.60 3.89% |
About 61% of BioArctic's investor base is looking to short. The analysis of current outlook of investing in BioArctic AB suggests that many traders are alarmed regarding BioArctic's prospects. The current market sentiment, together with BioArctic's historical and current headlines, can help investors time the market. In addition, many technical investors use BioArctic AB stock news signals to limit their universe of possible portfolio assets.
BioArctic |
BioArctic AB - New data from LEQEMBI phase 3 Clarity AD study ... Marketscreener.com
Read at news.google.com
 |
BioArctic Fundamental Analysis
We analyze BioArctic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioArctic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioArctic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
BioArctic is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
BioArctic AB Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioArctic stock to make a market-neutral strategy. Peer analysis of BioArctic could also be used in its relative valuation, which is a method of valuing BioArctic by comparing valuation metrics with similar companies.
Peers
BioArctic Related Equities
| HNSA | Hansa Biopharma | 1.11 |
| ||
| CANTA | Cantargia | 1.27 |
| ||
| ONCO | Oncopeptides | 1.33 |
| ||
| CAMX | Camurus AB | 2.62 |
|
Complementary Tools for BioArctic Stock analysis
When running BioArctic's price analysis, check to measure BioArctic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioArctic is operating at the current time. Most of BioArctic's value examination focuses on studying past and present price action to predict the probability of BioArctic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioArctic's price. Additionally, you may evaluate how the addition of BioArctic to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |